Literature DB >> 9671411

Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival.

M Fagioli1, M Alcalay, L Tomassoni, P F Ferrucci, A Mencarelli, D Riganelli, F Grignani, T Pozzan, I Nicoletti, F Grignani, P G Pelicci.   

Abstract

PML/RARalpha is the abnormal protein product of the Acute Promyelocytic Leukemia-specific 15;17 translocation. Both the PML and RARalpha components are required for the PML/RARalpha biological activities, namely its capacity to block differentiation and to increase survival of haematopoietic precursors. The physiological role of PML and its contribution to the function of the fusion protein are unknown. PML localizes to the cytoplasm and within specific nuclear bodies (NBs). In vitro, overexpression of PML correlates with suppression of cell transformation. The PML aminoterminal portion retained within the PML/RARalpha protein contains the RING finger, two newly defined cystein/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil region. We report here that PML has a growth suppressive activity in all the cell lines tested, regardless of their transformed phenotype, and that the cellular basis for the PML growth suppression is induction of apoptotic cell death. Analysis of various nuclear and cytoplasmic PML isoforms showed that the PML growth suppressive activity correlates with its nuclear localization. Analysis of the localization and growth suppressive activity demonstrated that: (i) the Ring + B1-B2 and coiled-coil regions are both indispensable and sufficient to target PML to the NBs; (ii) individual deletions of the various PML domains have no effect on its growth suppressor activity; (iii) the Ring + B1-B2 region exerts a partial growth suppressor activity but its fusion with the coiled-coil region is sufficient to recapitulate the suppressive function of wild type PML. These results indicate that PML is involved in cell survival regulation and that the PML component of the fusion protein (Ring + B1-B2 and coiled-coil regions) retains intact biological activity, thereby suggesting that the effects of PML/RARalpha on survival derive from the activation of the incorporated PML sequence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671411     DOI: 10.1038/sj.onc.1201811

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.

Authors:  Yunyun Geng; Shamci Monajembashi; Anwen Shao; Di Cui; Weiyong He; Zhongzhou Chen; Peter Hemmerich; Jun Tang
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

Review 2.  Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies.

Authors:  M Hodges; C Tissot; K Howe; D Grimwade; P S Freemont
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

3.  The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.

Authors:  M Alcalay; L Tomassoni; E Colombo; S Stoldt; F Grignani; M Fagioli; L Szekely; K Helin; P G Pelicci
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

4.  Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 5.  The role of PML in the nervous system.

Authors:  Paolo Salomoni; Joanne Betts-Henderson
Journal:  Mol Neurobiol       Date:  2010-12-15       Impact factor: 5.590

6.  WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies.

Authors:  Salah Mahmoudi; Sofia Henriksson; Irene Weibrecht; Stephen Smith; Ola Söderberg; Staffan Strömblad; Klas G Wiman; Marianne Farnebo
Journal:  PLoS Biol       Date:  2010-11-02       Impact factor: 8.029

7.  PML3 Orchestrates the Nuclear Dynamics and Function of TIP60.

Authors:  Quan Wu; Haixiang Hu; Jianping Lan; Chibuzo Emenari; Zhiyong Wang; Kang-Sang Chang; He Huang; Xuebiao Yao
Journal:  J Biol Chem       Date:  2009-01-16       Impact factor: 5.157

8.  Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA.

Authors:  F M Boisvert; M J Hendzel; D P Bazett-Jones
Journal:  J Cell Biol       Date:  2000-01-24       Impact factor: 10.539

9.  Deconstructing PML-induced premature senescence.

Authors:  Oliver Bischof; Olivier Kirsh; Mark Pearson; Koji Itahana; Pier Giuseppe Pelicci; Anne Dejean
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 14.012

10.  Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas.

Authors:  Toshihiro Matsuo; Takashi Sugita; Shoji Shimose; Tadahiko Kubo; Masataka Ishikawa; Yuji Yasunaga; Mitsuo Ochi
Journal:  J Exp Clin Cancer Res       Date:  2008-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.